Sanofi and MD Anderson Sign a Five-Year Pact to Expedite Oncology Research and Development

 Sanofi and MD Anderson Sign a Five-Year Pact to Expedite Oncology Research and Development

Sanofi and MD Anderson Sign a Five-Year Pact to Expedite Oncology Research and Development

Shots:

  • Sanofi and MD Anderson collaborated for 5yrs. to ramp up the development of investigational treatments, including targeted and immune-therapies for oncology patients. The alliance will support investigations into additional indications and combinations for studies already in the clinic
  • The collaboration will integrate MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies for better understanding of novel cancer drugs mechanism
  • New findings, large-scale molecular and phenotype datasets will be applied to the design of new translational studies on selected Sanofi molecules, and guide the selection of indications. The companies are expected to launch their first projects in summer 2020

Click here to­ read full press release/ article | Ref: Sanofi | Image: TechtrendsKE

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post